Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2018 Nov 15;4(Suppl 2):33-39.
doi: 10.1016/S2055-6640(20)30343-5.

Achieving UNAIDS 90-90-90 targets for pregnant and postpartum women in sub-Saharan Africa: progress, gaps and research needs

Lisa L Abuogi  1 , John M Humphrey  2 , Christian Mpody  3 , Marcel Yotebieng  3 , Pamela M Murnane  4 , Kate Clouse  5 , Lindah Otieno  6 , Craig R Cohen  7 , Kara Wools-Kaloustian  2
Affiliations
Editorial

Achieving UNAIDS 90-90-90 targets for pregnant and postpartum women in sub-Saharan Africa: progress, gaps and research needs

Lisa L Abuogi et al. J Virus Erad. .

Abstract

The implementation of the 2013 World Health Organization Option B+ recommendations for HIV treatment during pregnancy has helped drive significant progress in achieving universal treatment for pregnant and postpartum women in sub-Saharan Africa (SSA). Yet, critical research and implementation gaps exist in achieving the UNAIDS 90-90-90 targets. To help guide researchers, programmers and policymakers in prioritising these areas, we undertook a comprehensive review of the progress, gaps and research needs to achieve the 90-90-90 targets for this population in the Option B+ era, including early infant HIV diagnosis (EID) for HIV-exposed infants. Salient areas where progress has been achieved or where gaps remain include: (1) knowledge of HIV status is higher among people with HIV in southern and eastern Africa compared to western and central Africa (81% versus 48%, UNAIDS); (2) access to antiretroviral therapy (ART) for pregnant women has doubled in 22 of 42 SSA countries, but only six have achieved the second 90, and nearly a quarter of pregnant women initiating ART become lost to follow-up; (3) viral suppression data for this population are sparse (estimates range from 30% to 98% peripartum), with only half of women maintaining suppression through 12 months postpartum; and (4) EID rates range from 15% to 62%, with only three of 21 high-burden SSA countries testing >50% HIV-exposed infants within the first 2 months of life. We have identified and outlined promising innovations and research designed to address these gaps and improve the health of pregnant and postpartum women living with HIV and their infants.

Keywords: prevention of mother-to-child transmission, prevention of vertical transmission, HIV, pregnancy, postpartum, sub-Saharan Africa.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Antiretroviral therapy coverage for pregnant women living with HIV in sub-Saharan Africa, 2010–2016 (excluding single-dose nevirapine). Data from
See this image and copyright information in PMC

References

    1. World Health Organization Global guidance on criteria and processes for validation: Elimination of mother-to child transmission of HIV and syphilis . Geneva, Switzerland: WHO; 2017. Available at: www.who.int/reproductivehealth/publications/emtct-hiv-syphilis/en ( accessed September 2018).
    1. Joint United Nations Programme on HIV/AIDS (UNAIDS) 90-90-90: an ambitious treatment target to help end the AIDS epidemic. 2014. Available at: www.unaids.org/en/media/unaids/contentassets/documents/unaidspublication... ( accessed September 2018).
    1. UNAIDS Global AIDS Update 2016. 2016. Available at: www.unaids.org/sites/default/files/media_asset/global-AIDS-update-2016_e... ( accessed September 2018).
    1. UNAIDS 2015 Progress Report on the Global Plan. 2015. Available at: www.unaids.org/sites/default/files/media_asset/JC2774_2015ProgressReport... ( accessed September 2018).
    1. Fowler MG, Qin M, Fiscus SA et al. . Benefits and risks of antiretroviral therapy for perinatal HIV prevention. N Engl J Med 2016; 375: 1726– 1737. - PMC - PubMed

Publication types